US Stock Market Move | NVIDIA Corporation's competitor, Cerebras Systems (CBRS.US), opened with an increase of over 6%, and its revenue in 2025 saw a significant growth of 76%.
On Tuesday, AI chip manufacturer Cerebras Systems (CBRS.US) opened trading with an increase of over 6%, currently trading at $315.92.
On Tuesday, AI chip manufacturer Cerebras Systems (CBRS.US) opened more than 6% higher, now trading at $315.92. Last Thursday, Cerebras officially debuted on the US stock market. The company previously priced its IPO at $185 per share, raising about $5.5 billion, making it the largest IPO in the US market so far this year. As one of the key potential competitors of NVIDIA Corporation (NVDA.US), Cerebras, founded 11 years ago, has been focusing on developing high-performance AI chips, with clients and partners including AI industry giants like OpenAI.
According to the prospectus, Cerebras expects to achieve revenue of $510 million in 2025, a 76% year-on-year growth, and successfully "turn losses into profits" with a net profit of $238 million, earnings per share of $1.38, significantly improving from a loss per share of $9.90 in the previous year.
Related Articles

New Stock Outlook | Cutting Costs, Pressuring Costs, Losing Customers Three Major Cracks Behind the Silicon-Based Intelligent Light Ring

Industrial: Compared to the dot-com bubble, where is the current AI market heading?

New Stock News | Rongtai Pharmaceutical submits a second application to the Hong Kong Stock Exchange, becoming China's third-largest provider of digital marketing and supply chain services for the outpatient pharmaceutical market.
New Stock Outlook | Cutting Costs, Pressuring Costs, Losing Customers Three Major Cracks Behind the Silicon-Based Intelligent Light Ring

Industrial: Compared to the dot-com bubble, where is the current AI market heading?

New Stock News | Rongtai Pharmaceutical submits a second application to the Hong Kong Stock Exchange, becoming China's third-largest provider of digital marketing and supply chain services for the outpatient pharmaceutical market.






